glp-1 receptor agonist pancreatitis risk meta-analysis Glucagon-like peptide-1 agonists and of gastrointestinal cancers: A systematic review and of randomized controlled trials Glucagon-Like Peptide-1 Receptor Agonists and
Description
In addition, loss of muscle mass caused by some metabolic support programs may also accelerate the development of sarcopenia and age-related loss of muscle mass
Pharmacological treatment modalities such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become increasingly accepted as viable antidiabetic treatment options due to their safety and favorable cardiovascular profiles [9, 10]
4.7 Pregnancy-related effects Although type 2 diabetes and obesity have been effectively treated with GLP-1 receptor agonists, their role in pregnancy and breastfeeding has been a controversial debate due to potential risks to the mothers health and fetal outcomes (87)
We would probably not use GLP-1 analogues in an individual with significant glucose variability and a high risk of hypoglycaemia
16 Where did the concern for DR progression come from
